Overview
Neurexo Biosciences develops small-molecule therapeutics targeting synaptic plasticity pathways to treat treatment-resistant depression and post-traumatic stress disorder.
More in Neuropharmaceuticals
Latest industry news
Paradromics and Siemens Healthineers Launch Strategic Initiative to Build Advanced Imaging Foundation for BCIs
2026-10-19 · Industry
China's Neurotech Ambitions Signal a New Frontier in the Global Brain Race
2026-10-18 · Industry
Functional Ultrasound BCIs Cross a Threshold: From Brain Reading to Two-Way Control
2026-10-17 · Research
Visual Cues Are Quietly Skewing BCI Accuracy Scores, and the Field Is Taking Notice
2026-10-16 · Research
Company details
Category
💊 Neuropharmaceuticals
Location
San Diego, CA
Funding
Series A — $42M
Website
neurexobio.comListed
2026-10-19
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →